Corpus Intelligence IC Memo — CHILDRENS HOSPITAL LOS ANGELES 2026-04-26 03:45 UTC
IC Memo — CHILDRENS HOSPITAL LOS ANGELES
Investment Committee Memorandum | CA | 413 beds | Grade C | EBITDA uplift $88.9M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

CHILDRENS HOSPITAL LOS ANGELES

CCN 053302 | nan, CA | 413 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

CHILDRENS HOSPITAL LOS ANGELES is a 413-bed community hospital in nan, CA with $1.21B in net patient revenue and a -36.8% operating margin. The hospital serves a payer mix of 0.3% Medicare, 0.0% Medicaid, and 99.7% commercial.

Thesis: Undervalued. Our ML models identify $88.9M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -36.8% to -29.4% (+736bps).

Net Revenue HCRIS$1.21B
Current EBITDA COMPUTED$-444.5M
Operating Margin COMPUTED-36.8%
Occupancy HCRIS75.3%
Revenue / Bed COMPUTED$2.9M
Net-to-Gross HCRIS31.1%
Distress Probability MLnan%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
139
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of -36.8% places it below the state median. Among 139 size-comparable peers (206-826 beds), the median margin is -4.1%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (206-826), prioritizing same-state peers. 139 hospitals in the comp set.

HospitalStateBedsRevenueMargin
CHILDRENS HOSPITAL LOS ANGELES (Target)CA413$1.21B-36.8%
STANFORD HEALTH CARECA657$6.76B3.7%
UC DAVIS MEDICAL CENTERCA666$3.28B-11.5%
UCSD MEDICAL CENTERCA718$3.06B-7.2%
RONALD REAGAN UCLACA446$2.62B-6.8%
SANTA CLARA VALLEY MEDICAL CENCA805$2.55B-29.4%
LUCILE PACKARD CHILDRENS HOSPICA394$2.39B-0.8%
LOS ANGELES GENERAL MEDICAL CECA596$1.96B10.2%
UCI MEDICAL CENTERCA397$1.90B-2.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $88.9M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$25.4M+210bp18mo
Cost to Collect4.5%2.5%$24.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$23.9M+198bp12mo
A/R Days Reduction5200.0%3800.0%$14.7M+122bp9mo
Clean Claim Rate88.0%96.0%$773K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$25.4M
Cost to Collect
$24.2M
Denial Rate Reduction
$23.9M
A/R Days Reduction
$14.7M
Clean Claim Rate
$773K
Total EBITDA Uplift$88.9M
Current EBITDA$-444.5M
+ RCM Uplift+$88.9M
Pro Forma EBITDA$-355.5M
Current Margin-36.8%
Pro Forma Margin-29.4%
WC Released (1x)$46.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-683.8M$-2.04B0.00x-100.0%
Base (11x exit)10.0x11.0x$-683.8M$-2.47B0.00x-100.0%
Bull Case9.0x11.0x$-615.4M$-2.40B0.00x-100.0%
Bull (12x exit)9.0x12.0x$-615.4M$-2.80B0.00x-100.0%
Bear Case11.0x10.0x$-752.1M$-2.26B0.00x-100.0%
Bear (11x exit)11.0x11.0x$-752.1M$-2.74B0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 139 hospitals with 206-826 beds
  • Same-state prioritization (n=140)
  • Comp margins: P25=-15.0% / P50=-4.1% / P75=3.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.